B
Competitive
Oral division · Oral non-peptide GLP-1
Orforglipron
Eli Lilly · Foundayo · once daily
Approvedthe convenience play
Division standing
#2 of 2
Oral division
← Tolerability cost (bands)% body weight lost →
Notable09% vs placebo
Tolerability: the cost
Notable10.3% vs 2.7% placebo
AE-discontinuation +7.6 points, at the 17.2 mg daily. From ATTAIN-1.
Efficacy
9%17.2 mg · placebo-adjusted · 72 wk
ATTAIN-1: 11.1% vs 2.1% placebo, a 9-point gap on the treatment-regimen estimand.
The approved 17.2 mg tablet is bioequivalent to the 36 mg capsule used in ATTAIN-1, so these are the approved-dose figures.
Approved and much-hyped, but the verdict is Competitive, not class-leading. Its case is convenience, not the number.
Trails oral semaglutide on both efficacy and tolerability. Its case is convenience: a daily pill with no food or water restriction and scalable small-molecule supply, not potency.
Convenience profile: you weigh it, not us
Route
Oral pill
Frequency
Once daily
Food / water rule
None
Titration
Stepwise dose escalation
Storage
Room temperature
Supply
Small molecule, scalable manufacturing
Provenance: every number traces back
TrialATTAIN-1 · NCT05869903
Estimandtreatment-regimen estimand
Populationnon-diabetic obesity
Dose17.2 mg daily
SourceNEJM 2026; FDA approval (Foundayo), 1 Apr 2026
Verdict confirmed6 Jul 2026
Next milestone: Post-approval label expansionMechanism field guide →